Guest Seminar - A Peptidic Network Antibody Inhibits Both Angiogenesis and Inflammatory Response

Corneal neovascularization (CNV) is a global threat to human health. Traditional anti-angiogenesis agent may have therapy effect, while the inflammation in disease area remains unsolved. Herein, we reported two binding-induced fibrillogenesis (BIF) peptides as peptidic network antibodies for high-efficient and long-lasting anti-angiogenesis with reduced inflammatory response. BIF peptides could self-assemble into nanoparticles and further perform BIF behavior through binding integrin αvβ3, which is overexpressed on endothelial cells during angiogenesis. In vitro, the migration of integrin αvβ3 overexpressed endothelial cells was inhibited by BIF peptides. In vivo, one BIF peptide (0.012 mg/Kg) with 1.2% lower dose exhibited higher anti-angiogenesis effect than monoclonal antibody bevacizumab (0.96 mg/Kg) in a CNV rabbit model on day 14. Meanwhile, the inflammatory response, such as PI3 kinase/Akt pathway in CNV was successfully inhibited as well. The peptidic network antibody could block integrin αvβ3 via a long-term retention mode, which led to long-term therapeutic effect. The study provides a BIF peptide as promising therapeutic agent for both anti-angiogenesis and reduced inflammatory response.